NEU discontinued further development of the
NNZ-2566 compound
Glypromate drug after it failed to show an observable effect way back in December 2008.
The discontinued
TBI trials with
NNZ-2566 compound hasn't been part of NEU's development portfolio since Turnbull was PM - 2016.
As a refresher, NEU core development hub is around
NNZ-2591, targeting 6 neurological indications including ~
If you're looking for organic catalysts to the share price,
Q2/24 & Q3/24 loom as material, as to whether the hub and spoke potential of NNZ-2591 propels NEU towards a billion$+ sales portfolio. Only then will the hope of 'big-pharma' entering the picture become a possibility.
As it stands, NEUs akin to a mining exploration company commercialising exploration success into production - typically 10 years. The take-up of Daybue will be similar to increasing production grades along the way, and the balance of the NNZ-2591 development portfolio, brownfields exploration. Without the equivalent brownfield's success, or a fresh greenfield equivalent of a new compound via lab discovery, the potential for a M&A catalyst is significantly diminished.
(20min delay)